tyb
AF2 USAF VIP C-32A departed Erie Int'l Airport nw
SAM402 USAF G5 also departed Miami Int'l and begins descent towards Traverse City, M-POTUS' next stop
09-0015 USAF C-32A departed JBA to "pick up" POTUS and escort to Traverse City
09-0017 USAF C-23A departed Miami Int'l ne back to JBA
Back me or put IMF loans and EU visa-free deal at risk, Ukraine's president warns
KYIV (Reuters) - Ukrainian President Volodymyr Zelenskiy warned on Monday that foreign aid loans and a visa-free deal with the European Union were under threat if parliament did not restore anti-corruption reforms, saying the country could slide into “bloody chaos”. Zelenskiy has asked parliament to vote to dissolve the Constitutional Court and reinstate anti-corruption laws it struck down last week, but the outcome of the vote is uncertain.
In a possible signal he may dissolve parliament if lawmakers voted down new measures, Zelenskiy tweeted: “I want this parliament to work for the state. Whether the Verkhovna Rada [parliament] will continue to work will depend on the conclusions made by our deputies.” Ukraine’s patchy performance on reforms has impeded a $5 billion deal from the International Monetary Fund (IMF) to support the economy, which has been hit by the coronavirus pandemic.
The government is also under scrutiny after passing a resolution giving it more control over the procurement of medicines and equipment, but denies allegations this could be a vehicle for corruption. Zelenskiy told the ICTV news channel the IMF threatened to pull its support after the court verdict. Opposition parties say they will vote against Zelenskiy’s legislation, which former Prime Minister Yulia Tymoshenko described as a “coup d’etat” designed to concentrate more power in his hands.
It was unclear how many lawmakers from Zelenskiy’s Servant of the People party would support the bill. Lawmaker Halyna Yanchenko said Zelenskiy’s faction would back the legislation “if we do not find other, less painful solutions,” Interfax Ukraine reported. Zelenskiy said Ukrainians would not tolerate backsliding on reforms to fight corruption and that Ukraine’s reputation was at stake.
“Either the country will be thrown into bloody chaos again, or the state will end its existence as a system of transparent rules and agreements,” Zelenskiy said in an audio recording of an appeal to lawmakers obtained by the Liga.net news site.
https://www.reuters.com/article/ukraine-politics/update-1-back-me-or-put-imf-loans-and-eu-visa-free-deal-at-risk-ukraines-president-warns-idUSL1N2HO4AU
GORDO16 USAF E-4B Nightwatch done off southern Texas coast returning to Offutt AFB, Omaha
09-0015 USAF C-32A departed Selfridge Air Nat. Guard Base to meet POTUS in 16 when it departs
TEFLN11 USAF KC-135r tanker on station as the flying gas can
SAM402 USAF G5 se from Traverse City, MI
09-0016 USAF VIP POTUS C-32A departed Traverse City, MI to General Mitchell International Airport, Milwaukee, WI
(red dot)
SAM942 USAF G5 departed Traverse City, MI for Mitchell Airport
09-0015 USAF C-32A departed Selfridge Air Nat. Guard Base nw to central MI then south
TEFLN11 USAF KC-135r tanker on station as the flying gas can
0000000 US Army Blackhawk out of Kenosha Regional Airport
can't do nuffin about it at this point
I actually thought it would have been harder once the actual facts of wut habbened were able to be digested…but alas it did not go that way.
They have an absolute shit-show in general with the lackeys out in full force doing damage control.
I have not stopped going after them-too many.
Mirati Therapeutics sold by Boxer Capital LLC: $80.80m-Oct 30
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
https://www.marketscreener.com/quote/stock/MIRATI-THERAPEUTICS-INC-13643861/company/
Boxer Capital
Boxer Capital, LLC, is a private biotechnology investment fund based in San Diego, California that invents and invests in new therapeutics across multiple indications in order to create value through improved patient care and outcomes. Founded by the life sciences team at Tavistock Group in 2005, Boxer Capital invests in private and public companies representing the entire drug development lifecycle - from early-stage pre-clinical discovery assets to late-stage clinical and commercial stage companies.
https://www.boxercap.com/about-us/
Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706 shares sold by Mirati and 400,000 shares sold by a selling stockholder. This includes the exercise in full by the underwriters of their option to purchase up to 625,309 additional shares of common stock from Mirati and up to 25,000 additional shares of common stock from the selling stockholder. The aggregate gross proceeds to Mirati from this offering were approximately $926.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Goldman Sachs & Co. LLC, SVB Leerink LLC, Cowen and Company, LLC and Evercore Group, L.L.C. acted as joint book-running managers in the offering. Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Piper Sandler & Co. also acted as book-running managers in the offering.
https://www.marketscreener.com/quote/stock/MIRATI-THERAPEUTICS-INC-13643861/news/Mirati-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Unde-31671136/
https://www.finviz.com/insidertrading.ashx?oc=1465837&tc=7&b=2